ID   RASA1_HUMAN             Reviewed;        1047 AA.
AC   P20936; B2R6W3; B4DTL2; Q68CU6; Q9UDI1;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   18-JUN-2025, entry version 259.
DE   RecName: Full=Ras GTPase-activating protein 1;
DE            Short=GAP;
DE            Short=GTPase-activating protein;
DE            Short=RasGAP;
DE   AltName: Full=Ras p21 protein activator;
DE   AltName: Full=p120GAP;
GN   Name=RASA1; Synonyms=GAP, RASA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta;
RX   PubMed=3201259; DOI=10.1126/science.3201259;
RA   Trahey M., Wong G., Halenbeck R., Rubinfeld B., Martin G.A., Ladner M.,
RA   Long C.M., Crosier W.J., Watt K., Koths K., McCormick F.;
RT   "Molecular cloning of two types of GAP complementary DNA from human
RT   placenta.";
RL   Science 242:1697-1700(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 294-303; 326-334; 392-398; 439-457; 458-466; 479-483;
RP   777-790 AND 821-825, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=8360177; DOI=10.1016/s0021-9258(17)46708-1;
RA   Zhang Y., Zhang G., Mollat P., Carles C., Riva M., Frobert Y.,
RA   Malassine A., Rostene W., Thang D.C., Beltchev B., Tavitian A., Thane M.N.;
RT   "Purification, characterization, and cellular localization of the 100-kDa
RT   human placental GTPase-activating protein.";
RL   J. Biol. Chem. 268:18875-18881(1993).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-7 (ISOFORM 2).
RX   PubMed=2123878; DOI=10.1016/s0021-9258(18)45826-7;
RA   Halenbeck R., Crosier W.J., Clark R., McCormick F., Koths K.;
RT   "Purification, characterization, and western blot analysis of human GTPase-
RT   activating protein from native and recombinant sources.";
RL   J. Biol. Chem. 265:21922-21928(1990).
RN   [8]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=11389730; DOI=10.1046/j.1432-1327.2001.02230.x;
RA   Giglione C., Gonfloni S., Parmeggiani A.;
RT   "Differential actions of p60c-Src and Lck kinases on the Ras regulators
RT   p120-GAP and GDP/GTP exchange factor CDC25Mm.";
RL   Eur. J. Biochem. 268:3275-3283(2001).
RN   [9]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992;
RA   Kazlauskas A., Kashishian A., Cooper J.A., Valius M.;
RT   "GTPase-activating protein and phosphatidylinositol 3-kinase bind to
RT   distinct regions of the platelet-derived growth factor receptor beta
RT   subunit.";
RL   Mol. Cell. Biol. 12:2534-2544(1992).
RN   [10]
RP   INTERACTION WITH SQSTM1.
RX   PubMed=8618896; DOI=10.1073/pnas.92.26.12338;
RA   Park I., Chung J., Walsh C.T., Yun Y., Strominger J.L., Shin J.;
RT   "Phosphotyrosine-independent binding of a 62-kDa protein to the src
RT   homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of
RT   Ser-59 in the lck unique N-terminal region.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:12338-12342(1995).
RN   [11]
RP   INTERACTION WITH CAV2.
RX   PubMed=12091389; DOI=10.1074/jbc.m204367200;
RA   Lee H., Park D.S., Wang X.B., Scherer P.E., Schwartz P.E., Lisanti M.P.;
RT   "Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-
RT   caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated
RT   with lipid rafts/caveolae, but no longer forms a high molecular mass
RT   hetero-oligomer with caveolin-1.";
RL   J. Biol. Chem. 277:34556-34567(2002).
RN   [12]
RP   INTERACTION WITH CAV2.
RX   PubMed=15504032; DOI=10.1021/bi049295+;
RA   Wang X.B., Lee H., Capozza F., Marmon S., Sotgia F., Brooks J.W.,
RA   Campos-Gonzalez R., Lisanti M.P.;
RT   "Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the
RT   spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).";
RL   Biochemistry 43:13694-13706(2004).
RN   [13]
RP   INTERACTION WITH SPSB1.
RX   PubMed=15713673; DOI=10.1074/jbc.m413897200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET
RT   and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response
RT   element pathway.";
RL   J. Biol. Chem. 280:16393-16401(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-615, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [15]
RP   INTERACTION WITH PDPK1.
RX   PubMed=18024423; DOI=10.1074/jbc.m706361200;
RA   Yang K.J., Shin S., Piao L., Shin E., Li Y., Park K.A., Byun H.S., Won M.,
RA   Hong J., Kweon G.R., Hur G.M., Seok J.H., Chun T., Brazil D.P.,
RA   Hemmings B.A., Park J.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src
RT   involves tyrosine phosphorylation of PDK1 and Src homology 2 domain
RT   binding.";
RL   J. Biol. Chem. 283:1480-1491(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   INTERACTION WITH NCK1.
RX   PubMed=21664272; DOI=10.1016/j.cellsig.2011.05.019;
RA   Ger M., Zitkus Z., Valius M.;
RT   "Adaptor protein Nck1 interacts with p120 Ras GTPase-activating protein and
RT   regulates its activity.";
RL   Cell. Signal. 23:1651-1658(2011).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-831, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   INTERACTION WITH EPHB4.
RX   PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041;
RA   Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B.,
RA   Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A.,
RA   Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K.,
RA   Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S.,
RA   Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S.,
RA   Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A.,
RA   Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E.,
RA   Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M.,
RA   Lifton R.P., Kahle K.T.;
RT   "Mutations in chromatin modifier and ephrin signaling genes in vein of
RT   Galen malformation.";
RL   Neuron 101:429-443(2019).
RN   [22]
RP   STRUCTURE BY NMR OF 275-350.
RX   PubMed=8137811; DOI=10.1002/j.1460-2075.1994.tb06379.x;
RA   Yang Y.S., Garbay C., Duschesne M., Cornille F., Jullian N., Fromage N.,
RA   Tocque B., Roques B.P.;
RT   "Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of
RT   essential Ras signaling-involved sequence.";
RL   EMBO J. 13:1270-1279(1994).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 714-1047.
RX   PubMed=8955277; DOI=10.1038/384591a0;
RA   Scheffzek K., Lautwein A., Kabsch W., Reza Ahmadian M., Wittinghofer A.;
RT   "Crystal structure of the GTPase-activating domain of human p120GAP and
RT   implications for the interaction with Ras.";
RL   Nature 384:591-596(1996).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 714-1047 IN COMPLEX WITH RAS.
RX   PubMed=9219684; DOI=10.1126/science.277.5324.333;
RA   Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A.,
RA   Schmitz F., Wittinghofer A.;
RT   "The Ras-RasGAP complex: structural basis for GTPase activation and its
RT   loss in oncogenic Ras mutants.";
RL   Science 277:333-338(1997).
RN   [25]
RP   STRUCTURE BY NMR OF 282-446.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH3 domain and of the second SH2 domain of human
RT   RAS GTPase-activating protein 1.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [26]
RP   VARIANTS LEU-398; GLU-400 AND VAL-401.
RX   PubMed=8275088; DOI=10.1038/ng1193-242;
RA   Friedman E., Gejman P.V., Martin G.A., McCormick F.;
RT   "Nonsense mutations in the C-terminal SH2 region of the GTPase activating
RT   protein (GAP) gene in human tumours.";
RL   Nat. Genet. 5:242-247(1993).
RN   [27]
RP   VARIANT CMAVM1 TYR-540.
RX   PubMed=14639529; DOI=10.1086/379793;
RA   Eerola I., Boon L.M., Mulliken J.B., Burrows P.E., Dompmartin A.,
RA   Watanabe S., Vanwijck R., Vikkula M.;
RT   "Capillary malformation-arteriovenous malformation, a new clinical and
RT   genetic disorder caused by RASA1 mutations.";
RL   Am. J. Hum. Genet. 73:1240-1249(2003).
RN   [28]
RP   VARIANTS CMAVM1 CYS-528; ASP-530; GLU-626 AND VAL-763.
RX   PubMed=24038909; DOI=10.1002/humu.22431;
RA   Revencu N., Boon L.M., Mendola A., Cordisco M.R., Dubois J., Clapuyt P.,
RA   Hammer F., Amor D.J., Irvine A.D., Baselga E., Dompmartin A., Syed S.,
RA   Martin-Santiago A., Ades L., Collins F., Smith J., Sandaradura S.,
RA   Barrio V.R., Burrows P.E., Blei F., Cozzolino M., Brunetti-Pierri N.,
RA   Vicente A., Abramowicz M., Desir J., Vilain C., Chung W.K., Wilson A.,
RA   Gardiner C.A., Dwight Y., Lord D.J., Fishman L., Cytrynbaum C., Chamlin S.,
RA   Ghali F., Gilaberte Y., Joss S., Boente Mdel C., Leaute-Labreze C.,
RA   Delrue M.A., Bayliss S., Martorell L., Gonzalez-Ensenat M.A.,
RA   Mazereeuw-Hautier J., O'Donnell B., Bessis D., Pyeritz R.E., Salhi A.,
RA   Tan O.T., Wargon O., Mulliken J.B., Vikkula M.;
RT   "RASA1 mutations and associated phenotypes in 68 families with capillary
RT   malformation-arteriovenous malformation.";
RL   Hum. Mutat. 34:1632-1641(2013).
CC   -!- FUNCTION: Inhibitory regulator of the Ras-cyclic AMP pathway.
CC       Stimulates the GTPase of normal but not oncogenic Ras p21; this
CC       stimulation may be further increased in the presence of NCK1.
CC       {ECO:0000269|PubMed:11389730, ECO:0000269|PubMed:8360177}.
CC   -!- SUBUNIT: Interacts with SQSTM1. Interacts with SPSB1; the interaction
CC       does not promote degradation. Interacts with CAV2 (tyrosine
CC       phosphorylated form). Directly interacts with NCK1. Interacts with
CC       PDGFRB (tyrosine phosphorylated). Interacts (via SH2 domain) with the
CC       'Tyr-9' phosphorylated form of PDPK1. Interacts with tyrosine-
CC       phosphorylated EPHB4 (PubMed:8955277). {ECO:0000269|PubMed:12091389,
CC       ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:15504032,
CC       ECO:0000269|PubMed:15713673, ECO:0000269|PubMed:18024423,
CC       ECO:0000269|PubMed:21664272, ECO:0000269|PubMed:8618896,
CC       ECO:0000269|PubMed:8955277, ECO:0000269|PubMed:9219684}.
CC   -!- INTERACTION:
CC       P20936; Q8IZP0: ABI1; NbExp=2; IntAct=EBI-1026476, EBI-375446;
CC       P20936; P10275: AR; NbExp=16; IntAct=EBI-1026476, EBI-608057;
CC       P20936; P04632: CAPNS1; NbExp=3; IntAct=EBI-1026476, EBI-711828;
CC       P20936; Q03135: CAV1; NbExp=2; IntAct=EBI-1026476, EBI-603614;
CC       P20936; Q96QB1: DLC1; NbExp=7; IntAct=EBI-1026476, EBI-2608428;
CC       P20936; P00533: EGFR; NbExp=7; IntAct=EBI-1026476, EBI-297353;
CC       P20936; P04626: ERBB2; NbExp=8; IntAct=EBI-1026476, EBI-641062;
CC       P20936; P21860: ERBB3; NbExp=6; IntAct=EBI-1026476, EBI-720706;
CC       P20936; P36888: FLT3; NbExp=2; IntAct=EBI-1026476, EBI-3946257;
CC       P20936; Q13480: GAB1; NbExp=25; IntAct=EBI-1026476, EBI-517684;
CC       P20936; Q96IK5: GMCL1; NbExp=3; IntAct=EBI-1026476, EBI-2548508;
CC       P20936; P42858: HTT; NbExp=3; IntAct=EBI-1026476, EBI-466029;
CC       P20936; P10721: KIT; NbExp=16; IntAct=EBI-1026476, EBI-1379503;
CC       P20936; P08581: MET; NbExp=15; IntAct=EBI-1026476, EBI-1039152;
CC       P20936; P16333: NCK1; NbExp=6; IntAct=EBI-1026476, EBI-389883;
CC       P20936; P09619: PDGFRB; NbExp=3; IntAct=EBI-1026476, EBI-641237;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:8360177}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P20936-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P20936-2; Sequence=VSP_001625, VSP_001626;
CC       Name=3;
CC         IsoId=P20936-3; Sequence=VSP_057434, VSP_057435;
CC       Name=4;
CC         IsoId=P20936-4; Sequence=VSP_057432, VSP_057433;
CC   -!- TISSUE SPECIFICITY: In placental villi, detected only in the
CC       trophoblast layer (cytotrophoblast and syncytiotrophoblast). Not
CC       detected in stromal, endothelial or Hofbauer cells (at protein level).
CC       {ECO:0000269|PubMed:8360177}.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- PTM: Phosphorylated by SRC and LCK. The phosphorylation SRC inhibits
CC       its ability to stimulate the Ras-GTPase activity, whereas
CC       phosphorylation by LCK does not display any effect on stimulation
CC       activity. {ECO:0000269|PubMed:11389730}.
CC   -!- DISEASE: Note=Mutations in the SH2 domain of RASA seem to be oncogenic
CC       and cause basal cell carcinomas.
CC   -!- DISEASE: Capillary malformation-arteriovenous malformation 1 (CMAVM1)
CC       [MIM:608354]: A disorder characterized by atypical capillary
CC       malformations that are multiple, small, round to oval in shape and
CC       pinkish red in color. These capillary malformations are associated with
CC       either arteriovenous malformation, arteriovenous fistula, or Parkes
CC       Weber syndrome. CMAVM1 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:14639529, ECO:0000269|PubMed:24038909}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23379; AAA52517.1; -; mRNA.
DR   EMBL; M23612; AAA35865.1; -; mRNA.
DR   EMBL; AK300263; BAG62024.1; -; mRNA.
DR   EMBL; AK312739; BAG35610.1; -; mRNA.
DR   EMBL; CR749722; CAH18488.2; -; mRNA.
DR   EMBL; AC010410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC018754; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC035142; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC126776; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC033015; AAH33015.1; -; mRNA.
DR   CCDS; CCDS34200.1; -. [P20936-1]
DR   CCDS; CCDS47243.1; -. [P20936-2]
DR   PIR; A40121; A40121.
DR   PIR; B40121; B40121.
DR   RefSeq; NP_002881.1; NM_002890.3. [P20936-1]
DR   RefSeq; NP_072179.1; NM_022650.3. [P20936-2]
DR   PDB; 1WER; X-ray; 1.60 A; A=714-1047.
DR   PDB; 1WQ1; X-ray; 2.50 A; G=714-1047.
DR   PDB; 2GQI; NMR; -; A=282-339.
DR   PDB; 2GSB; NMR; -; A=341-446.
DR   PDB; 2J05; X-ray; 1.50 A; A/B=281-341.
DR   PDB; 2J06; X-ray; 1.80 A; A/B=281-341.
DR   PDB; 2M51; NMR; -; A=281-341.
DR   PDB; 4FSS; X-ray; 2.25 A; A/B/C=281-341.
DR   PDB; 6PXB; X-ray; 1.75 A; A/B/C/D/E/F=174-280.
DR   PDB; 6PXC; X-ray; 1.60 A; A=174-280.
DR   PDB; 6WAX; X-ray; 1.50 A; A/B=340-444.
DR   PDB; 6WAY; X-ray; 1.50 A; A=340-444.
DR   PDB; 8BOS; X-ray; 2.10 A; G=713-1042.
DR   PDB; 8DGQ; X-ray; 1.95 A; A/B=174-444.
DR   PDB; 9BZ4; X-ray; 2.45 A; A/B/C/D=581-1047.
DR   PDBsum; 1WER; -.
DR   PDBsum; 1WQ1; -.
DR   PDBsum; 2GQI; -.
DR   PDBsum; 2GSB; -.
DR   PDBsum; 2J05; -.
DR   PDBsum; 2J06; -.
DR   PDBsum; 2M51; -.
DR   PDBsum; 4FSS; -.
DR   PDBsum; 6PXB; -.
DR   PDBsum; 6PXC; -.
DR   PDBsum; 6WAX; -.
DR   PDBsum; 6WAY; -.
DR   PDBsum; 8BOS; -.
DR   PDBsum; 8DGQ; -.
DR   PDBsum; 9BZ4; -.
DR   AlphaFoldDB; P20936; -.
DR   BMRB; P20936; -.
DR   SASBDB; P20936; -.
DR   SMR; P20936; -.
DR   BioGRID; 111856; 143.
DR   CORUM; P20936; -.
DR   DIP; DIP-144N; -.
DR   FunCoup; P20936; 3541.
DR   IntAct; P20936; 139.
DR   MINT; P20936; -.
DR   STRING; 9606.ENSP00000274376; -.
DR   GlyGen; P20936; 1 site, 2 N-linked glycans (1 site).
DR   iPTMnet; P20936; -.
DR   MetOSite; P20936; -.
DR   PhosphoSitePlus; P20936; -.
DR   SwissPalm; P20936; -.
DR   BioMuta; RASA1; -.
DR   DMDM; 121743; -.
DR   CPTAC; CPTAC-1548; -.
DR   jPOST; P20936; -.
DR   MassIVE; P20936; -.
DR   PaxDb; 9606-ENSP00000274376; -.
DR   PeptideAtlas; P20936; -.
DR   ProteomicsDB; 5112; -.
DR   ProteomicsDB; 53828; -. [P20936-1]
DR   ProteomicsDB; 53829; -. [P20936-2]
DR   ProteomicsDB; 66031; -.
DR   Pumba; P20936; -.
DR   ABCD; P20936; 9 sequenced antibodies.
DR   Antibodypedia; 24766; 537 antibodies from 36 providers.
DR   DNASU; 5921; -.
DR   Ensembl; ENST00000274376.11; ENSP00000274376.6; ENSG00000145715.15. [P20936-1]
DR   Ensembl; ENST00000456692.6; ENSP00000411221.2; ENSG00000145715.15. [P20936-2]
DR   Ensembl; ENST00000512763.5; ENSP00000422008.1; ENSG00000145715.15. [P20936-4]
DR   Ensembl; ENST00000515800.6; ENSP00000423395.2; ENSG00000145715.15. [P20936-3]
DR   GeneID; 5921; -.
DR   KEGG; hsa:5921; -.
DR   MANE-Select; ENST00000274376.11; ENSP00000274376.6; NM_002890.3; NP_002881.1.
DR   UCSC; uc003kiw.4; human. [P20936-1]
DR   UCSC; uc011ctv.3; human.
DR   UCSC; uc063fdq.1; human.
DR   AGR; HGNC:9871; -.
DR   CTD; 5921; -.
DR   DisGeNET; 5921; -.
DR   GeneCards; RASA1; -.
DR   GeneReviews; RASA1; -.
DR   HGNC; HGNC:9871; RASA1.
DR   HPA; ENSG00000145715; Tissue enhanced (placenta).
DR   MalaCards; RASA1; -.
DR   MIM; 139150; gene.
DR   MIM; 608354; phenotype.
DR   neXtProt; NX_P20936; -.
DR   OpenTargets; ENSG00000145715; -.
DR   Orphanet; 90307; Parkes Weber syndrome.
DR   Orphanet; 693907; RASA1-related capillary malformation-arteriovenous malformation.
DR   PharmGKB; PA34232; -.
DR   VEuPathDB; HostDB:ENSG00000145715; -.
DR   eggNOG; KOG3508; Eukaryota.
DR   GeneTree; ENSGT00940000155846; -.
DR   HOGENOM; CLU_500517_0_0_1; -.
DR   InParanoid; P20936; -.
DR   OMA; KMGSYLV; -.
DR   OrthoDB; 1562946at2759; -.
DR   PAN-GO; P20936; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; P20936; -.
DR   TreeFam; TF105301; -.
DR   PathwayCommons; P20936; -.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases.
DR   SignaLink; P20936; -.
DR   SIGNOR; P20936; -.
DR   BioGRID-ORCS; 5921; 12 hits in 1168 CRISPR screens.
DR   ChiTaRS; RASA1; human.
DR   EvolutionaryTrace; P20936; -.
DR   GeneWiki; RAS_p21_protein_activator_1; -.
DR   GenomeRNAi; 5921; -.
DR   Pharos; P20936; Tbio.
DR   PRO; PR:P20936; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P20936; protein.
DR   Bgee; ENSG00000145715; Expressed in endothelial cell and 213 other cell types or tissues.
DR   ExpressionAtlas; P20936; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; NAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0001726; C:ruffle; IEA:Ensembl.
DR   GO; GO:0005096; F:GTPase activator activity; EXP:Reactome.
DR   GO; GO:0003924; F:GTPase activity; TAS:Reactome.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:CAFA.
DR   GO; GO:0019870; F:potassium channel inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0048514; P:blood vessel morphogenesis; IMP:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; NAS:UniProtKB.
DR   GO; GO:0000281; P:mitotic cytokinesis; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; NAS:UniProtKB.
DR   GO; GO:0051252; P:regulation of RNA metabolic process; NAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   CDD; cd08400; C2_Ras_p21A1; 1.
DR   CDD; cd13260; PH_RASA1; 1.
DR   CDD; cd05391; RasGAP_p120GAP; 1.
DR   CDD; cd10354; SH2_Cterm_RasGAP; 1.
DR   CDD; cd10353; SH2_Nterm_RasGAP; 1.
DR   CDD; cd11788; SH3_RasGAP; 1.
DR   FunFam; 1.10.506.10:FF:000007; RAS p21 protein activator 1; 1.
DR   FunFam; 2.30.29.30:FF:000090; RAS p21 protein activator 1; 1.
DR   FunFam; 2.30.30.40:FF:000050; RAS p21 protein activator 1; 1.
DR   FunFam; 2.60.40.150:FF:000052; RAS p21 protein activator 1; 1.
DR   FunFam; 3.30.505.10:FF:000033; RAS p21 protein activator 1; 1.
DR   FunFam; 3.30.505.10:FF:000046; RAS p21 protein activator 1; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039360; Ras_GTPase.
DR   InterPro; IPR035842; RasGAP_C_SH2.
DR   InterPro; IPR023152; RasGAP_CS.
DR   InterPro; IPR001936; RasGAP_dom.
DR   InterPro; IPR035841; RasGAP_N_SH2.
DR   InterPro; IPR035652; RasGAP_SH3.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10194:SF146; RAS GTPASE-ACTIVATING PROTEIN 1; 1.
DR   PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00616; RasGAP; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00323; RasGAP; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF55550; SH2 domain; 2.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1.
DR   PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm;
KW   Direct protein sequencing; Disease variant; GTPase activation;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Repeat;
KW   SH2 domain; SH3 domain; Tumor suppressor.
FT   CHAIN           1..1047
FT                   /note="Ras GTPase-activating protein 1"
FT                   /id="PRO_0000056636"
FT   DOMAIN          181..272
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          279..341
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          351..441
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          474..577
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          577..690
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          764..974
FT                   /note="Ras-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   SITE            789
FT                   /note="Arginine finger; crucial for GTP hydrolysis by
FT                   stabilizing the transition state"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         615
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..177
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:3201259"
FT                   /id="VSP_001625"
FT   VAR_SEQ         1..13
FT                   /note="MMAAEAGSEEGGP -> MRTGYSSVPSKLR (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_057432"
FT   VAR_SEQ         14..180
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_057433"
FT   VAR_SEQ         178..180
FT                   /note="TNQ -> MKG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:3201259"
FT                   /id="VSP_001626"
FT   VAR_SEQ         538..539
FT                   /note="PN -> CS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_057434"
FT   VAR_SEQ         540..1047
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_057435"
FT   VARIANT         398
FT                   /note="R -> L (in basal cell carcinomas;
FT                   dbSNP:rs137853214)"
FT                   /evidence="ECO:0000269|PubMed:8275088"
FT                   /id="VAR_002650"
FT   VARIANT         400
FT                   /note="K -> E (in basal cell carcinomas;
FT                   dbSNP:rs137853215)"
FT                   /evidence="ECO:0000269|PubMed:8275088"
FT                   /id="VAR_002651"
FT   VARIANT         401
FT                   /note="I -> V (in basal cell carcinomas;
FT                   dbSNP:rs137853216)"
FT                   /evidence="ECO:0000269|PubMed:8275088"
FT                   /id="VAR_002652"
FT   VARIANT         528
FT                   /note="Y -> C (in CMAVM1; uncertain significance;
FT                   dbSNP:rs145752649)"
FT                   /evidence="ECO:0000269|PubMed:24038909"
FT                   /id="VAR_072088"
FT   VARIANT         530
FT                   /note="V -> D (in CMAVM1)"
FT                   /evidence="ECO:0000269|PubMed:24038909"
FT                   /id="VAR_072089"
FT   VARIANT         540
FT                   /note="C -> Y (in CMAVM1; dbSNP:rs137853217)"
FT                   /evidence="ECO:0000269|PubMed:14639529"
FT                   /id="VAR_017744"
FT   VARIANT         626
FT                   /note="A -> E (in CMAVM1; dbSNP:rs745690594)"
FT                   /evidence="ECO:0000269|PubMed:24038909"
FT                   /id="VAR_072090"
FT   VARIANT         763
FT                   /note="E -> V (in CMAVM1; uncertain significance;
FT                   dbSNP:rs373098580)"
FT                   /evidence="ECO:0000269|PubMed:24038909"
FT                   /id="VAR_072091"
FT   CONFLICT        789
FT                   /note="R -> A (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           178..180
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          182..186
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   HELIX           188..198
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          203..212
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          216..221
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:6PXB"
FT   STRAND          227..235
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          238..241
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          244..248
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   HELIX           249..258
FT                   /evidence="ECO:0007829|PDB:6PXC"
FT   STRAND          283..288
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   STRAND          296..298
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   STRAND          306..312
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   STRAND          316..322
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   TURN            323..325
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   STRAND          328..332
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   HELIX           333..335
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   STRAND          336..338
FT                   /evidence="ECO:0007829|PDB:2J05"
FT   TURN            345..348
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          350..352
FT                   /evidence="ECO:0007829|PDB:2GSB"
FT   HELIX           358..367
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          374..378
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          380..382
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          386..391
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          396..403
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   TURN            405..407
FT                   /evidence="ECO:0007829|PDB:2GSB"
FT   STRAND          409..411
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   STRAND          414..417
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   HELIX           419..428
FT                   /evidence="ECO:0007829|PDB:6WAX"
FT   HELIX           720..723
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           724..730
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           736..744
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   STRAND          746..748
FT                   /evidence="ECO:0007829|PDB:1WQ1"
FT   HELIX           749..762
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           766..780
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           784..786
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   TURN            787..789
FT                   /evidence="ECO:0007829|PDB:1WQ1"
FT   HELIX           793..805
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           807..823
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           832..834
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           841..860
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           861..865
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           868..884
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           891..900
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   TURN            901..904
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           905..910
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   TURN            912..916
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           924..941
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   STRAND          946..949
FT                   /evidence="ECO:0007829|PDB:1WQ1"
FT   HELIX           951..956
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           957..974
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           992..1004
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           1006..1013
FT                   /evidence="ECO:0007829|PDB:1WER"
FT   HELIX           1020..1038
FT                   /evidence="ECO:0007829|PDB:1WER"
SQ   SEQUENCE   1047 AA;  116403 MW;  C35B6567F5BC5370 CRC64;
     MMAAEAGSEE GGPVTAGAGG GGAAAGSSAY PAVCRVKIPA ALPVAAAPYP GLVETGVAGT
     LGGGAALGSE FLGAGSVAGA LGGAGLTGGG TAAGVAGAAA GVAGAAVAGP SGDMALTKLP
     TSLLAETLGP GGGFPPLPPP PYLPPLGAGL GTVDEGDSLD GPEYEEEEVA IPLTAPPTNQ
     WYHGKLDRTI AEERLRQAGK SGSYLIRESD RRPGSFVLSF LSQMNVVNHF RIIAMCGDYY
     IGGRRFSSLS DLIGYYSHVS CLLKGEKLLY PVAPPEPVED RRRVRAILPY TKVPDTDEIS
     FLKGDMFIVH NELEDGWMWV TNLRTDEQGL IVEDLVEEVG REEDPHEGKI WFHGKISKQE
     AYNLLMTVGQ VCSFLVRPSD NTPGDYSLYF RTNENIQRFK ICPTPNNQFM MGGRYYNSIG
     DIIDHYRKEQ IVEGYYLKEP VPMQDQEQVL NDTVDGKEIY NTIRRKTKDA FYKNIVKKGY
     LLKKGKGKRW KNLYFILEGS DAQLIYFESE KRATKPKGLI DLSVCSVYVV HDSLFGRPNC
     FQIVVQHFSE EHYIFYFAGE TPEQAEDWMK GLQAFCNLRK SSPGTSNKRL RQVSSLVLHI
     EEAHKLPVKH FTNPYCNIYL NSVQVAKTHA REGQNPVWSE EFVFDDLPPD INRFEITLSN
     KTKKSKDPDI LFMRCQLSRL QKGHATDEWF LLSSHIPLKG IEPGSLRVRA RYSMEKIMPE
     EEYSEFKELI LQKELHVVYA LSHVCGQDRT LLASILLRIF LHEKLESLLL CTLNDREISM
     EDEATTLFRA TTLASTLMEQ YMKATATQFV HHALKDSILK IMESKQSCEL SPSKLEKNED
     VNTNLTHLLN ILSELVEKIF MASEILPPTL RYIYGCLQKS VQHKWPTNTT MRTRVVSGFV
     FLRLICPAIL NPRMFNIISD SPSPIAARTL ILVAKSVQNL ANLVEFGAKE PYMEGVNPFI
     KSNKHRMIMF LDELGNVPEL PDTTEHSRTD LSRDLAALHE ICVAHSDELR TLSNERGAQQ
     HVLKKLLAIT ELLQQKQNQY TKTNDVR
//
